98 related articles for article (PubMed ID: 14612999)
1. [From the gene to the clinic: prostate cancer death can now be an exception?].
Labrie F; Cusan L; Gomez JL; Candas B; Bélanger A; Luu-The V; Labrie C; Simard J
Med Sci (Paris); 2003 Oct; 19(10):910-9. PubMed ID: 14612999
[TBL] [Abstract][Full Text] [Related]
2. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
3. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
4. Is dehydroepiandrosterone a hormone?
Labrie F; Luu-The V; Bélanger A; Lin SX; Simard J; Pelletier G; Labrie C
J Endocrinol; 2005 Nov; 187(2):169-96. PubMed ID: 16293766
[TBL] [Abstract][Full Text] [Related]
5. Major impact of hormonal therapy in localized prostate cancer--death can already be an exception.
Labrie F; Cusan L; Gomez J; Luu-The V; Candas B; Bélanger A; Labrie C
J Steroid Biochem Mol Biol; 2004 Dec; 92(5):327-44. PubMed ID: 15698538
[TBL] [Abstract][Full Text] [Related]
6. Science behind total androgen blockade: from gene to combination therapy.
Labrie F; Bélanger A; Dupont A; Luu-The V; Simard J; Labrie C
Clin Invest Med; 1993 Dec; 16(6):475-92. PubMed ID: 8013153
[TBL] [Abstract][Full Text] [Related]
7. Screening and hormonal therapy of localized prostate cancer shows major benefits on survival.
Labrie F
Cancer J; 2000 Apr; 6 Suppl 2():S182-7. PubMed ID: 10803834
[TBL] [Abstract][Full Text] [Related]
8. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
[TBL] [Abstract][Full Text] [Related]
9. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
10. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
Akaza H
BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
[TBL] [Abstract][Full Text] [Related]
11. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
12. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
13. Endocrine therapy for prostate cancer.
Labrie F
Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.
Labrie F; Bélanger A; Luu-The V; Labrie C; Simard J; Cusan L; Gomez J; Candas B
Endocr Rev; 2005 May; 26(3):361-79. PubMed ID: 15867098
[TBL] [Abstract][Full Text] [Related]
15. Current status and prospects of androgen depletion therapy for prostate cancer.
Akaza H
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
17. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
18. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
[TBL] [Abstract][Full Text] [Related]
20. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
